About to have lift off...I think, page-117

Thank you melenova - my FA is the reason why I decided to temporarily absorb significant six figure paper losses from $1; I work in healthcare which makes me biased as to LBT's value from a Societal/clinical dimension. APAS justifies itself more in a recession as labs/hospitals need to continue to make money (maximise profit whilst doing same activity) via payback analysis and IRR - and is more attractive as an add on in an expansionary economy cycle (more activity for less) - it makes sense to puchase an APAS from every angle - as a doctor/clinician, hospital CFO, Ramsay shareholder, private health insurance (less costs) - but more importantly as a patient - I know my problem faster and can get treated and be better faster/go back to work faster - there's a dime to be made from APAS every way you slice it - no matter the economic climate.

I did some back reading (back in March!), I enjoyed our exchange of knowledge, research and analysis - a good debate and exchange of information. LBT achieved its goals and milestones, as hard as it was.

At the time - I didn't appreciate the magnitude of APAS, that artificial intelligence in the FDA realm is a radical affair - it forced the FDA to create a new classification framework. Given the thernos saga - and their failure to obtain similar FDA approvals (and being valued at $xx billions by Silicon Valley) - the FDA was rightfully cautious to take their time, and in fact be more inclined to reject radical innovations such as APAS.

Given hindsight, APAS is classified more as a drug in the eyes of the FDA (therapeutics than diagnostic) and thus warranted a more conservative timeframe.

In a hospital/lab and clinical workflow framework, given the FDA approval you could logically combine APAS to interface with pharmacy automation projects - it could technically diagnose and dispense drugs to treat patients - with automated follow up diagnostic to determine efficacy of dispensed drugs - optimising treatment protocols and customising compound drugs... the possibilities are endless, and it will depend on the creativity of our global diagnostic partners with US$xx billions in market cap to exploit potential revenues and profits - to distribute and market the potential applications.

The best layman analogy in view of the the FDA is that if you it were to approve APAS... could you drop it as as a consumer/patient facing diagnostic+treatment vending machine, but instead of serving Coca Cola - you cured patients based on infectious diseases - automatically.

Literally drop an APAS incubot + Pharmacy Automation dispensary module into remote regions of the world - and you would save/improve millions of lives...

Thought experiment - should the The Bill Gates foundation offer to buy us out and roll us out to the less privileged - saving millions of lives would you agree to sell your shares to Gates at your personal breakeven point?